Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET)
We live in a golden age for the development of innovative radiotherapy technologies. Three major new treatment platforms are currently at various stages of being implemented globally: stereotactic ablative radiotherapy (SABR)[1]; MR-guided radiotherapy (MR-Linac)[2]; and proton beam therapy (PBT)[3...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2017
|
| _version_ | 1826277239920001024 |
|---|---|
| author | Harrington, K Hall, E Hawkins, M Henry, A MacKay, R Maughan, T McDonald, A Nutting, C Oelfke, U Sebag-Montefiore, D Sharma, R van Herk, M Faivre-Finn, C |
| author_facet | Harrington, K Hall, E Hawkins, M Henry, A MacKay, R Maughan, T McDonald, A Nutting, C Oelfke, U Sebag-Montefiore, D Sharma, R van Herk, M Faivre-Finn, C |
| author_sort | Harrington, K |
| collection | OXFORD |
| description | We live in a golden age for the development of innovative radiotherapy technologies. Three major new treatment platforms are currently at various stages of being implemented globally: stereotactic ablative radiotherapy (SABR)[1]; MR-guided radiotherapy (MR-Linac)[2]; and proton beam therapy (PBT)[3]. Such technologies offer huge opportunities for clinical benefit, but also present significant challenges for development, assessment and rational implementation within an increasingly financially constrained National Health Service (NHS). However, the apparent restrictions imposed by the structure of the NHS can also be viewed as a benefit for developing and proving the value of new radiotherapy technologies. In large part, this is due to the need to provide robust evidence to support the implementation of new technological developments before they can become widely available nationally. For example, the recent development, assessment and widespread adoption of intensity-modulated radiotherapy (IMRT) in the UK was driven by a programme of preclinical and clinical studies that were led initially by a small number of academic centres, but which progressively involved and finally included the majority of radiotherapy units in the UK[4-7]. A by-product of this research is that the UK has provided the international community with the best evidence-base for the use of IMRT in a variety of indications (e.g. prostate, breast and head and neck cancers). |
| first_indexed | 2024-03-06T23:25:55Z |
| format | Journal article |
| id | oxford-uuid:6a5c562b-ef12-410c-8377-7478e0b0008d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:25:55Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:6a5c562b-ef12-410c-8377-7478e0b0008d2022-03-26T18:57:01ZIntroducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6a5c562b-ef12-410c-8377-7478e0b0008dEnglishSymplectic Elements at OxfordElsevier2017Harrington, KHall, EHawkins, MHenry, AMacKay, RMaughan, TMcDonald, ANutting, COelfke, USebag-Montefiore, DSharma, Rvan Herk, MFaivre-Finn, C We live in a golden age for the development of innovative radiotherapy technologies. Three major new treatment platforms are currently at various stages of being implemented globally: stereotactic ablative radiotherapy (SABR)[1]; MR-guided radiotherapy (MR-Linac)[2]; and proton beam therapy (PBT)[3]. Such technologies offer huge opportunities for clinical benefit, but also present significant challenges for development, assessment and rational implementation within an increasingly financially constrained National Health Service (NHS). However, the apparent restrictions imposed by the structure of the NHS can also be viewed as a benefit for developing and proving the value of new radiotherapy technologies. In large part, this is due to the need to provide robust evidence to support the implementation of new technological developments before they can become widely available nationally. For example, the recent development, assessment and widespread adoption of intensity-modulated radiotherapy (IMRT) in the UK was driven by a programme of preclinical and clinical studies that were led initially by a small number of academic centres, but which progressively involved and finally included the majority of radiotherapy units in the UK[4-7]. A by-product of this research is that the UK has provided the international community with the best evidence-base for the use of IMRT in a variety of indications (e.g. prostate, breast and head and neck cancers). |
| spellingShingle | Harrington, K Hall, E Hawkins, M Henry, A MacKay, R Maughan, T McDonald, A Nutting, C Oelfke, U Sebag-Montefiore, D Sharma, R van Herk, M Faivre-Finn, C Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET) |
| title | Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET) |
| title_full | Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET) |
| title_fullStr | Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET) |
| title_full_unstemmed | Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET) |
| title_short | Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET) |
| title_sort | introducing the cancer research uk advanced radiotherapy technologies network art net |
| work_keys_str_mv | AT harringtonk introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT halle introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT hawkinsm introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT henrya introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT mackayr introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT maughant introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT mcdonalda introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT nuttingc introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT oelfkeu introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT sebagmontefiored introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT sharmar introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT vanherkm introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet AT faivrefinnc introducingthecancerresearchukadvancedradiotherapytechnologiesnetworkartnet |